Wall Street Zen Upgrades Terns Pharmaceuticals (NASDAQ:TERN) to “Hold”

Terns Pharmaceuticals (NASDAQ:TERN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other research analysts have also issued research reports about the company. BMO Capital Markets raised their target price on Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Barclays lifted their price objective on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. UBS Group upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. Oppenheimer boosted their price target on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Finally, Leerink Partners began coverage on shares of Terns Pharmaceuticals in a research report on Monday, February 9th. They issued an “outperform” rating and a $58.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Terns Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

Terns Pharmaceuticals Price Performance

Shares of TERN opened at $37.79 on Friday. Terns Pharmaceuticals has a one year low of $1.87 and a one year high of $48.26. The stock has a 50-day moving average of $38.73 and a 200-day moving average of $21.15. The company has a market cap of $3.92 billion, a PE ratio of -36.69 and a beta of -0.28.

Insider Activity

In related news, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the sale, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Amy L. Burroughs sold 71,339 shares of Terns Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the completion of the sale, the chief executive officer directly owned 138,976 shares in the company, valued at approximately $5,294,985.60. This represents a 33.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 141,243 shares of company stock valued at $5,311,090. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. DLD Asset Management LP bought a new position in Terns Pharmaceuticals during the second quarter valued at $138,000. AlphaQuest LLC lifted its position in shares of Terns Pharmaceuticals by 9,088,200.0% during the 3rd quarter. AlphaQuest LLC now owns 90,883 shares of the company’s stock valued at $683,000 after buying an additional 90,882 shares during the last quarter. Candriam S.C.A. lifted its position in shares of Terns Pharmaceuticals by 9.9% during the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock valued at $8,834,000 after buying an additional 214,266 shares during the last quarter. Franklin Resources Inc. bought a new position in shares of Terns Pharmaceuticals during the 2nd quarter worth $4,765,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Terns Pharmaceuticals in the 2nd quarter worth about $4,774,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.